San Jose Compounding Pharmacy (White House Pharmacy, Inc.), San Jose, CA

Is San Jose Compounding Pharmacy (White House Pharmacy, Inc.) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does San Jose Compounding Pharmacy (White House Pharmacy, Inc.) hold a California pharmacy license?

No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones.

Has San Jose Compounding Pharmacy (White House Pharmacy, Inc.) had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 state handoff letter (Dec 21, 2021) and 1 FMD-145 letter (Dec 21, 2021) for San Jose Compounding Pharmacy (White House Pharmacy, Inc.). State board actions: record found. The California State Board of Pharmacy’s posted disciplinary decisions on facility licenses lists “Through a disciplinary action of the Board, the license is voluntarily surrendered” dated Feb 8, 2023, case AC 6802 on license PHY 54957. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
White House Pharmacy, Inc.; San Jose Compounding Pharmacy
Location
San Jose, CA
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
0
Warning letters on FDA’s actions page
0
Latest action on that page
Dec 21, 2021
FDA Data Dashboard inspections
1 inspection: 1 NAI; 1 published Form 483
Form 483 text on this page
1 Form 483, 4 observations
State board records
No exact match

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as White House Pharmacy, Inc., (dba San Jose Compounding Pharmacy), a 503A facility, with 2 dated actions.

Document
Dec 21, 2021State handoff letterState Handoff Letter Issued 12/21/2021Not linked by FDA
Dec 21, 2021FMD-145 letterFMD-145 Letter Issued 12/21/2021Not linked by FDA

An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists White House Pharmacy Inc., San Jose, CA (FEI number 3002946561), matched to this page by exact name, city and state. It lists 1 inspection: 1 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Jun 15, 2021No Action Indicated (NAI)Drug Quality Assurance (Drugs)30029465611146258

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 4 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Sep 4, 2018 to Sep 14, 2018: 4 observations

Firm on the cover
White House Pharmacy Inc. dba San Jose Compounding Pharmacy, 2453 Forest Ave, San Jose, CA 95128-1505
Establishment type on the cover
Producer of Non-Sterile Drug Products
FDA district office on the cover
1431 Harbor Bay Parkway Alameda, CA 94502-7070
Matched to this page by
firm name, city and state on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

You produced beta-lactam mugs without providing adequate containment, segregation, cleaning ofwork surfaces, cleaning of utensils and cleaning ofpersonnel to prevent cross-contamination .

a)

Specifically, your firm produced beta-lactam products <Redacted B4> (times . on the same day and in the same day (Lab Room) as non-beta lactam products. Your film produces beta-lactam products on a shared table within 2 feet distance of non-beta lactam products. This table shows the date made, beta-lactam and quantity of non-beta lactam product produced.

Number of Non-Beta Lactam Products Produced in the Lab Room on the Same Day

Beta-Lactam Produced in Lab Room

Date Made

Amoxicillin/Clavulanate 50MG/12.5MG/ML

<Redacted B4>

1/3/2017 Amoxicillin 350 MG Suppository Amoxicillin 350 MG Supposito1y 5/18/2017 Amoxicillin 100 MG Chew Amoxicillin 100 MG Chew 7/5/2017 Amoxicillin 100 MG Chew Amoxicillin 100 MG Chew

Amoxicillin 500MG/ML Suspension

<Redacted B4>

Amoxicillin 500MG/ML Suspension

Amoxicillin 500MG/ML Suspension

Penicillamine 125 MG Capsule

Ceftazidime 500 MG Suppository

Ceftazidime 500 MG Suppository

Penicillamine 125 MG Capsule

Penicillamine 125 MG Capsule

Penicillamine 125 MG Capsule ...

Read the full 483 (PDF on fda.gov)

Observation 2

You produced highly potent diugs without providing adequate containment, segregation, cleaning ofwork surfaces, cleaning ofutensils and cleaning ofpersonnel to prevent cross-contamination.

41 Specifically, your firm produced <Redacted B4> prescriptions of Hydroocodone Bitartrate 10 MG capsules and <Redacted B4> prescriptions of Fentanyl Sorbitol Base (Veggie) 500 MCG Lollipops from 10/31/2016-9/6/2018.

a) Your firm produced the Hydrocodone Bitartrate 10 MG capsules and the Fentanyl Sorbitol Base (Veggie) 500 MCG Lollipops in your Lab Room, while other patient specific prescriptions were being produced, on a shared table with limited space. Your pharmacy technician stated up to <Redacted B4> different products can be produced at one time.

b) Your firm cleans work surfaces with <Redacted B4> and daily equipment (used to produce highly potent products) with <Redacted B4> and <Redacted B4> Iwhich is not effective in removing highly potent residues.

Observation 3

You produced hazardous diugs without providing adequate cleaning of work surfaces and cleaning of utensils to prevent cross-contamination.

Specifically, you produce patient specific prescriptions from hormonal Active Pharmaceutical Ingredients (APis), such as Testosterone and Progesterone in your Hazardous Room at the same time as other hazardous products. Between 6/1/2018 and 9/4/2018, your firm produced <Redacted B4> progesterone prescriptions.

a) Your written procedure entitled, "Cleaning and Maintenance of the Non-Sterile Compounding Area" SOP Number: 3.050 states in Section 10.0, "Approved cleaning solutions are <Redacted B4> or <Redacted B4> . Approved decontaminating solution is <Redacted B4> . " The above listed cleaning and decontaminating solutions used to clean work surfaces and dirty equipment in your Hazardous Room and are not effective in deactivating hazardous drugs.

Observation 4

You used a non-pharmaceutical grade component in the formulation of a drug product.

On 8/23/2018, your firm produced <Redacted B4> capsules of Progesterone 100 MG capsules with a non-pharmaceutical grade component, namely food grade <Redacted B4> Lot# <Redacted B4> Expiration Date: 8/8/2019) manufactured by <Redacted B4>

a) You stated that your firm ran out of <Redacted B4> and purchased food grade <Redacted B4> from the grocery store to produce the Progesterone 100 MG capsules.

State board of pharmacy records

No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones. Board file.

Board actions

As the board words them, newest first. An entry that is a complaint, charge or notice the board filed is a charge, not a final decision; only an order or final action records the outcome.

What this covers: Facility license decisions from the board’s quarterly Disciplinary Actions pages (87 of 88 quarters had a facility section). These are final decisions; accusations filed and immediate protection orders are not included. Actions in the data are dated Jan 5, 2005 to Oct 28, 2026.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.